MFIMFI
HRTX icon

Mesirow Financial Investment Management - Fixed Income’s Heron Therapeutics HRTX Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,010
Closed -$435K – 129
2017
Q1 		$435K Buy
+29,010
New +$402K 0.03% 113

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's HRTX Position: Q2 2017 in Review

Mesirow Financial Investment Management - Fixed Income sold out of Heron Therapeutics (HRTX) in Q2 2017, closing a stake of 29,010 shares — an estimated $435K sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in HRTX in Q1 2017 and held it in 1 quarter. The position peaked at $435K in Q1 2017. 104 funds tracked by Wall St. Rank hold HRTX as of Q2 2017.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining Heron Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 29,010 Heron Therapeutics shares in Q2 2017, an estimated $435K.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in Heron Therapeutics in Q1 2017 and held it in 1 quarter.
  • Mesirow Financial Investment Management - Fixed Income's Heron Therapeutics position peaked at $435K in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2017.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q2 2017, filed 1 Aug 2017.